Department of Psychiatry and Behavioral Sciences, University of Texas McGovern Medical School, Houston, TX, USA.
Translational Imaging Center, Houston Methodist Research Institute, Weill Cornell College of Medicine, Houston, TX, USA.
Mol Psychiatry. 2022 Feb;27(2):831-839. doi: 10.1038/s41380-021-01365-x. Epub 2021 Oct 29.
Behavioral conditioning and expectation can have profound impact on animal and human physiology. Placebo, administered under positive expectation in clinical trials, can have potent effects on disease pathology, obscuring active medications. Emerging evidence suggests placebo-responsive neurotransmitter systems (e.g., endogenous opioid) regulate immune function by manipulating inflammatory proteins including IL-18, a potent pro-inflammatory, nociceptive cytokine implicated in pathophysiology of various diseases. Validation that neuroimmune interactions involving brain μ-opioid receptor (MOR) activity and plasma IL-18 underlie placebo analgesic expectation could have widespread clinical applications. Unfortunately, current lack of mechanistic clarity obfuscates clinical translation. To elucidate neuroimmune interactions underlying placebo analgesia, we exposed 37 healthy human volunteers to a standardized pain challenge on each of 2 days within a Positron Emission Tomography (PET) neuroimaging paradigm using the MOR selective radiotracer, C-Carfentanil (CFN). Each day volunteers received an intervention (placebo under analgesic expectation or no treatment), completed PET scanning, and rated their pain experience. MOR BP parametric maps were generated from PET scans using standard methods. Results showed placebo reduced plasma IL-18 during pain (W = -3.7, p < 0.001), the extent correlating with reduction in pain scores. Placebo reduction in IL-18 covaried with placebo-induced endogenous opioid release in the left nucleus accumbens (T = 3.33; p < 0.001) and left amygdala (T = 3.30; p < 0.001). These findings are consistent with a modulating effect of placebo (under analgesic expectation in humans) on a potent nociceptive, pro-inflammatory cytokine (IL-18) and underlying relationships with endogenous opioid activity, a neurotransmitter system critically involved in pain, stress, and mood regulation.
行为条件作用和期望可以对动物和人类的生理产生深远的影响。在临床试验中,基于积极期望给予安慰剂,可能对疾病的病理产生强大的影响,掩盖了活性药物的作用。新出现的证据表明,安慰剂反应性神经递质系统(例如内源性阿片类系统)通过调节炎症蛋白,包括白细胞介素-18(IL-18),来调节免疫功能,白细胞介素-18 是一种强烈的促炎、痛觉敏化细胞因子,与各种疾病的病理生理学有关。验证涉及脑 μ-阿片受体(MOR)活性和血浆 IL-18 的神经免疫相互作用是安慰剂镇痛期望的基础,这可能具有广泛的临床应用。不幸的是,目前缺乏机制上的明确性,使得临床转化变得复杂。为了阐明安慰剂镇痛的神经免疫相互作用,我们在正电子发射断层扫描(PET)神经影像学范式内的 2 天内,每天对 37 名健康的人类志愿者进行标准化疼痛挑战,使用 MOR 选择性放射性示踪剂 C-Carfentanil(CFN)。每天志愿者接受一种干预措施(镇痛期望下的安慰剂或无治疗),完成 PET 扫描,并对他们的疼痛体验进行评分。使用标准方法从 PET 扫描中生成 MOR BP 参数图。结果表明,安慰剂在疼痛期间降低了血浆 IL-18(W=-3.7,p<0.001),其程度与疼痛评分的降低相关。IL-18 的安慰剂降低与左伏隔核(T=3.33;p<0.001)和左杏仁核(T=3.30;p<0.001)中内源性阿片释放的安慰剂诱导减少相关。这些发现与安慰剂(在人类中具有镇痛期望)对一种有效的痛觉敏化、促炎细胞因子(IL-18)的调节作用一致,并且与内源性阿片活性相关,内源性阿片活性是参与疼痛、应激和情绪调节的关键神经递质系统。